SEARCH:   Advanced

Blood, 13 August 2009, Vol. 114, No. 7, pp. 1314-1318. Prepublished online as a Blood First Edition Paper on June 17, 2009; DOI 10.1182/blood-2008-12-193250. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-12-193250v1 114/7/1314    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Stanulla, M. Articles by Schwab, M. PubMed PubMed Citation Articles by Stanulla, M. Articles by Schwab, M. Related Collections Free Research Articles Lymphoid Neoplasia Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocols Martin Stanulla1,*, Elke Schaeffeler2,*, Anja Möricke1, Sally A. Coulthard3, Gunnar Cario1, André Schrauder1, Peter Kaatsch4, Michael Dördelmann5, Karl Welte5, Martin Zimmermann5, Alfred Reiter6, Michel Eichelbaum2, Hansjörg Riehm5, Martin Schrappe1, and Matthias Schwab2,7 1 University Children's Hospital, Kiel, Germany; 2 Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany; 3 Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom; 4 German Childhood Cancer Registry, Institute of Medical Biometrics, Epidemiology, and Informatics (IMBEI), Mainz, Germany; 5 Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany; 6 Pediatric Hematology and Oncology, University Children's Hospital Giessen, Giessen, Germany; and 7 Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen, Germany Thiopurine methyltransferase (TPMT)is involved in the metabolism of thiopurines such as 6-mercaptopurine and 6-thioguanine. TPMT activity is significantly altered by genetics, and heterozygous and even more homozygous variant people reveal substiantially decreased TPMT activity. Treatment for childhood acute lymphoblastic leukemia (ALL) regularly includes the use of thiopurine drugs. Importantly, childhood ALL patients with low TPMT activity have been considered to be at increased risk of developing therapy-associated acute myeloid leukemia and brain tumors. In the present study, we genotyped 105 of 129 patients who developed a secondary malignant neoplasm after ALL treatment on 7 consecutive German Berlin-Frankfurt-Münster trials for all functionally relevant TPMT variants. Frequencies of TPMT variants were similarly distributed in secondary malignant neoplasm patients and the overall ALL patient population of 814 patients. Thus, TPMT does not play a major role in the etiology of secondary malignant neoplasm after treatment for childhood ALL, according to Berlin-Frankfurt-Münster strategies. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020